153 related articles for article (PubMed ID: 37047202)
1. HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via
Clayton NS; Carter EP; Fearon AE; Heward JA; Rodríguez Fernández L; Boughetane L; Wilkes EH; Cutillas PR; Grose RP
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047202
[TBL] [Abstract][Full Text] [Related]
2. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
3. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
4. Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
Li G; Wang X; Hibshoosh H; Jin C; Halmos B
PLoS One; 2014; 9(9):e106349. PubMed ID: 25238247
[TBL] [Abstract][Full Text] [Related]
5. PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.
Fearon AE; Carter EP; Clayton NS; Wilkes EH; Baker AM; Kapitonova E; Bakhouche BA; Tanner Y; Wang J; Gadaleta E; Chelala C; Moore KM; Marshall JF; Chupin J; Schmid P; Jones JL; Lockley M; Cutillas PR; Grose RP
Cell Rep; 2018 Feb; 22(9):2469-2481. PubMed ID: 29490281
[TBL] [Abstract][Full Text] [Related]
6. HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.
Wehrenberg-Klee E; Sinevici N; Nesti S; Kalomeris T; Austin E; Larimer B; Mahmood U
Mol Imaging Biol; 2021 Dec; 23(6):930-940. PubMed ID: 34101105
[TBL] [Abstract][Full Text] [Related]
7. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
Liu L; Greger J; Shi H; Liu Y; Greshock J; Annan R; Halsey W; Sathe GM; Martin AM; Gilmer TM
Cancer Res; 2009 Sep; 69(17):6871-8. PubMed ID: 19671800
[TBL] [Abstract][Full Text] [Related]
8. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.
Huang WC; Hung CM; Wei CT; Chen TM; Chien PH; Pan HL; Lin YM; Chen YJ
Oncotarget; 2016 Sep; 7(38):62352-62363. PubMed ID: 27694691
[TBL] [Abstract][Full Text] [Related]
10. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
12. miR-221 confers lapatinib resistance by negatively regulating p27
Huynh TK; Huang CH; Chen JY; Yao JH; Yang YS; Wei YL; Chen HF; Chen CH; Tu CY; Hsu YM; Liu LC; Huang WC
Cancer Sci; 2021 Oct; 112(10):4234-4245. PubMed ID: 34382727
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Menendez JA
J Cell Physiol; 2011 Jan; 226(1):52-7. PubMed ID: 20658522
[TBL] [Abstract][Full Text] [Related]
14. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
15. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
[TBL] [Abstract][Full Text] [Related]
16. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
Gayle SS; Arnold SL; O'Regan RM; Nahta R
Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
Gayle SS; Castellino RC; Buss MC; Nahta R
Curr Med Chem; 2013; 20(19):2486-99. PubMed ID: 23531216
[TBL] [Abstract][Full Text] [Related]
19. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
